References
- Parkin D.M., Muir C.S., Whelan S.L., Gao Y-T., Ferlay J., Powell J. Cancer Incidence in Five Continents. IARC Scientific Publications, Lyon 1992; Vol. 6
- Chen M.F., Jeng L.B. Partial hepatic resection for hepatocellular carcinoma. J. Gastroenterol. Hepatol. 1997; 12: S329–S334
- Benvegnu L., Fattovich G., Noventa F., Tremolada F., Chemello L., Cechetto A., Alberti A. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Cancer 1994; 74: 2442–2448
- Dorr R.T. Interferon-α in malignant and viral diseases: an overview. Drugs 1993; 45: 177–211
- Daniels H.M., Meager A., Eddleston A.L., Alexander G.J., Williams R. Spontaneous production of tumour necrosis factor α and interleukin-1 beta during interferon-α treatment of chronic HBV infection. Lancet 1990; 335: 875–877
- Hoofnagle J.H., Dusheiko G.M., Seeff L.B., Jones E.A., Waggoner J.G., Bales Z.B. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann. Intern. Med. 1981; 94: 744–748
- Effect of interferon-α on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 1998; 351: 1535–1539
- Woo M.H., Burnakis T.G. Interferon α in the treatment of chronic viral hepatitis B and C. Ann. Pharmacother. 1997; 31: 330–336
- Finter N.B. The subtypes of α-interferon and their importance. Proceedings of the 2nd International Symposium on Lymphob α-interferon, Barcelona, Spain, F. Dianzani, J.P. Valtuena, 1994; 1–6
- Oon C.J. Long term survival following treatment of hepatocellular carcinoma in Singapore: evaluation of Wellferon in the prophylaxis of high risk pre-cancerous conditions. Cancer Chemother. Pharmacol. 1992; 31: S137–S142
- Tsukuma H., Hiyama T., Tanaka S., Nakao M., Yabuuchi T., Kitamura T., Nakanishi K., Fujimoto I., Inoue A., Yamazaki H. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N. Engl. J. Med. 1993; 328: 1797–1801
- Castilla A., Prieto J., Fausto N. Transforming growth factors β1 and α in chronic liver disease: effects of interferon α therapy. N. Engl. J. Med. 1991; 324: 933–940
- Lin S.M., Sheen I.S., Chien R.N., Chu C.M., Liaw Y.F. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29: 971–975
- Harada H., Kitagawa M., Tanaka N., Yamamoto H., Harada K., Ishihara M., Taniguchi T. Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2. Science 1993; 259: 971–974
- Ikeda K., Saitoh S., Suzuki Y., Kobayashi M., Tsubota A., Fukuda M., Koida I., Arase Y., Chayama K., Murashima N., Kumada H. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus, a pilot study. Cancer 1998; 82: 827–835
- Yoshida H., Shiratori Y., Moriyama M., Arakawa Y., Ide T., Sata M., Inoue O., Yano M., Tanaka M., Fujiyama S., Nishiguchi S., Kuroki T., Imazeki F., Yokosuka O., Kinoyama S., Yamada G., Omata M. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann. Intern. Med. 1999; 131: 174–181